Table 6.
Study | Patients (n = 16) |
Sex | Age | ACHD type | NOAC * | Bleeding Location | Indication | CHA2D2-VASC | HAS-BLED | Risk Factors and Comorbidities |
---|---|---|---|---|---|---|---|---|---|---|
Yang [28] | 1 | F | 56 | Fontan | Apixaban | Gastrointestinal | AtrialArrhythmia | 2 | 1 | Mitral Regurgitation |
Yang [28] | 2 | F | 71 | PAPVC | Rivaroxaban | Gastrointestinal | AtrialArrhythmia | 3 | 1 | Tricuspid Regurgitation |
Yang [28] | 3 | F | 23 | CoA | Rivaroxaban | Menorrhagia | AtrialArrhythmia | 2 | 0 | Bioprosthetic AVand PV |
Yang [28] | 4 | F | 42 | Eisenmenger | Rivaroxaban | Menorrhagia | Pulmonary Embolism | 3 | 2 | - |
Yang [28] | 5 | F | 41 | Fontan | Apixaban | Menorrhagia | Atrial Arrhythmia | 4 | 0 | Mitral Valve Regurgitation |
Yang [28] | 6 | M | 80 | ToF | Apixaban | Hematuria | AtrialArrhythmia | 4 | 1 | Pulmonary Stenosis |
Yang [28] | 7 | F | 67 | Fontan | Rivaroxaban | Menorrhagia | AtrialArrhythmia | 2 | 2 | - |
Pujol [29] | 8 | M | 59 | PFO | Apixaban 5 mg b.i.d | Cranial | PTP | 3 | 3 | Aspirin Arterial Hypertension |
Pujol [29] | 9 | F | 48 | TGA-Mustard | Rivaroxaban 20 mg q.d | Cranial | PTP | 2 | 0 | Oral Contraception |
Pujol [29] | 10 | M | 26 | PA + VSD, PH Deletion 22q11 | Rivaroxaban 10 mg q.d | Gastrointestinal | PTP | 1 | 3 | Renal Insufficiency, Cyanosis, Bleeding under VKA |
Pujol [29] | 11 | M | 65 | ASD | Apixaban 2.5 mg b.i.d | Intraoccular | PTP | 3 | 2 | Arterial Hypertension Smoker |
Pujol [29] | 12 | F | 44 | PA + VSDPAH | Apixaban 5 mg b.i.d | Intraarticular | PTP | 2 | 0 | Renal Insufficiency, Diabetes Mellitus |
Pujol [29] | 13 | F | 46 | Marfan | Rivaroxaban 20 mg q.d | Intraarticular | PTP | 2 | 0 | Smoker |
Pujol [29] | 14 | F | 43 | ASD | Rivaroxaban 20 mg q.d | Intramuscular | PTP | 1 | 0 | - |
Pujol [29] | 15 | F | 34 | PFO | Edoxaban 60 mg q.d | Vaginal | PTP | 3 | 3 | Bleeding under VKA |
Pujol [29] | 16 | F | 42 | VSD (corrected) | Rivaroxaban 20 mg q.d | Vaginal | PTP | 1 | 0 | - |
Abbreviations: M: Male; F: Female; PAPVC: partial anomalous pulmonary venous connection; CoA: coarctation of the aorta; ToF: tetralogy of fallot; PFO: persistent foramen ovale; VSD: ventricular Septal defect; ASD: atrial septal defect; PTP: primary thromboprophylaxis; TGA: transposition of great arteries; AV: aortic valve; PV: pulmonary valve; b.i.d: twice a day; q.d; once a day. * NOAC dose indicated where reported.